Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma (Jun 2022)
Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma (Aug 2020)
p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status (Jun 2017)